Developing inhaled bioengineered exosome therapeutics for the treatment of lung cancer
What is INSPIRE?
INSPIRE is an innovative project aiming to go beyond the state of the art to combine advances in gene therapy, regenerative medicine, and preclinical modelling with cutting edge manufacturing technology to deliver advanced therapeutics that can change the paradigm of treating lung cancer.
The goal of the project is to create an allogeneic ‘off the shelf’ advanced therapeutic gene therapy with regenerative medicine properties. This novel advanced therapy has the required complexity to address a wide variety of lung cancers irrespective of phenotype or driver mutations. This ambitious goal will be realised by harnessing the proprietary technologies of OmniSpirant, Aerogen & EVerZom to produce EVs carrying recombinant therapeutic RNAs that are delivered by state-of-the-art aerosol technology.
Grant agreement number 101057777
EC contribution 12, 778, 595.00 EUROS
Duration 36 months
Starting date 1 June 2022
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101057777. This publication reflects only the author’s views and the European Union is not liable for any use that may be made of the information contained therein.